private:stemgent
|
345803
|
Jun 3rd, 2019 12:00AM
|
Stemgent, Inc.
|
1.3K
|
16.00
|
Open
|
Biotechnology
|
Jun 3rd, 2019 12:31PM
|
Jun 3rd, 2019 12:31PM
|
Stemgent, part of the ReproCELL Group, is a leading supplier of cellular reprogramming products and services and tissue-based research, and provides a comprehensive portfolio of tools for cell research, and is recognized as expert in stem cell reprogramming, provide mRNA reprogramming systems, cell culture media, antibodies, small molecules, and iPS reprogramming services.
ReproCELL Incorporated
ReproCELL was established as a venture company originating from the University of Tokyo and Kyoto University and has been the pioneer in the iPS cell business, succeeding in the commercialization of the world's first human iPS cell products in 2009 and with the world's most advanced research and technology. In addition, through the recent acquisitions of Reinnervate (UK), BioServe (US), and Stemgent (US), ReproCELL is proceeding towards the establishment of a global distribution network, and technology synergy and new product introductions.
|
Open
|
mRNA reprogramming systems and services, Reagents for pluripotent cell culture and differentiation, Global supplier of human tissue and biofluids, Target and biomarker validation services, Compound profiling services in cell-based assays
|
Open
|
4 Hartwell Place
|
Lexington
|
MA
|
US
|
02421
|
|
Stemgent
|
|
Pharmaceuticals & Biotechnology
|
private:stemgent
|
345803
|
Feb 17th, 2018 12:00AM
|
Stemgent, Inc.
|
1.2K
|
19.00
|
Open
|
Biotechnology
|
Feb 17th, 2018 02:25PM
|
Feb 17th, 2018 02:25PM
|
Stemgent, part of the ReproCELL Group, is a leading supplier of cellular reprogramming products and services and tissue-based research, and provides a comprehensive portfolio of tools for cell research, and is recognized as expert in stem cell reprogramming, provide mRNA reprogramming systems, cell culture media, antibodies, small molecules, and iPS reprogramming services. ReproCELL Incorporated ReproCELL was established as a venture company originating from the University of Tokyo and Kyoto University and has been the pioneer in the iPS cell business, succeeding in the commercialization of the world's first human iPS cell products in 2009 and with the world's most advanced research and technology. In addition, through the recent acquisitions of Reinnervate (UK), BioServe (US), and Stemgent (US), ReproCELL is proceeding towards the establishment of a global distribution network, and technology synergy and new product introductions.
|
|
|
|
|
|
|
|
|
|
Stemgent
|
|
Pharmaceuticals & Biotechnology
|
private:stemgent
|
345803
|
Feb 16th, 2018 12:00AM
|
Stemgent, Inc.
|
1.2K
|
19.00
|
Open
|
Biotechnology
|
Feb 16th, 2017 08:15AM
|
Feb 16th, 2017 08:15AM
|
Stemgent, part of the ReproCELL Group, is a leading supplier of cellular reprogramming products and services and tissue-based research, and provides a comprehensive portfolio of tools for cell research, and is recognized as expert in stem cell reprogramming, provide mRNA reprogramming systems, cell culture media, antibodies, small molecules, and iPS reprogramming services.
ReproCELL Incorporated
ReproCELL was established as a venture company originating from the University of Tokyo and Kyoto University and has been the pioneer in the iPS cell business, succeeding in the commercialization of the world's first human iPS cell products in 2009 and with the world's most advanced research and technology. In addition, through the recent acquisitions of Reinnervate (UK), BioServe (US), and Stemgent (US), ReproCELL is proceeding towards the establishment of a global distribution network, and technology synergy and new product introductions.
|
|
|
|
|
|
|
|
|
|
Stemgent
|
|
Pharmaceuticals & Biotechnology
|
private:stemgent
|
345803
|
Feb 15th, 2018 12:00AM
|
Stemgent, Inc.
|
1.2K
|
19.00
|
Open
|
Biotechnology
|
Feb 15th, 2017 10:07AM
|
Feb 15th, 2017 10:07AM
|
Stemgent, part of the ReproCELL Group, is a leading supplier of cellular reprogramming products and services and tissue-based research, and provides a comprehensive portfolio of tools for cell research, and is recognized as expert in stem cell reprogramming, provide mRNA reprogramming systems, cell culture media, antibodies, small molecules, and iPS reprogramming services.
ReproCELL Incorporated
ReproCELL was established as a venture company originating from the University of Tokyo and Kyoto University and has been the pioneer in the iPS cell business, succeeding in the commercialization of the world's first human iPS cell products in 2009 and with the world's most advanced research and technology. In addition, through the recent acquisitions of Reinnervate (UK), BioServe (US), and Stemgent (US), ReproCELL is proceeding towards the establishment of a global distribution network, and technology synergy and new product introductions.
|
|
|
|
|
|
|
|
|
|
Stemgent
|
|
Pharmaceuticals & Biotechnology
|
private:stemgent
|
345803
|
Feb 14th, 2018 12:00AM
|
Stemgent, Inc.
|
1.2K
|
19.00
|
Open
|
Biotechnology
|
Feb 14th, 2017 01:50PM
|
Feb 14th, 2017 01:50PM
|
Stemgent, part of the ReproCELL Group, is a leading supplier of cellular reprogramming products and services and tissue-based research, and provides a comprehensive portfolio of tools for cell research, and is recognized as expert in stem cell reprogramming, provide mRNA reprogramming systems, cell culture media, antibodies, small molecules, and iPS reprogramming services.
ReproCELL Incorporated
ReproCELL was established as a venture company originating from the University of Tokyo and Kyoto University and has been the pioneer in the iPS cell business, succeeding in the commercialization of the world's first human iPS cell products in 2009 and with the world's most advanced research and technology. In addition, through the recent acquisitions of Reinnervate (UK), BioServe (US), and Stemgent (US), ReproCELL is proceeding towards the establishment of a global distribution network, and technology synergy and new product introductions.
|
|
|
|
|
|
|
|
|
|
Stemgent
|
|
Pharmaceuticals & Biotechnology
|
private:stemgent
|
345803
|
Feb 13th, 2018 12:00AM
|
Stemgent, Inc.
|
1.2K
|
19.00
|
Open
|
Biotechnology
|
Feb 13th, 2017 04:11PM
|
Feb 13th, 2017 04:11PM
|
Stemgent, part of the ReproCELL Group, is a leading supplier of cellular reprogramming products and services and tissue-based research, and provides a comprehensive portfolio of tools for cell research, and is recognized as expert in stem cell reprogramming, provide mRNA reprogramming systems, cell culture media, antibodies, small molecules, and iPS reprogramming services.
ReproCELL Incorporated
ReproCELL was established as a venture company originating from the University of Tokyo and Kyoto University and has been the pioneer in the iPS cell business, succeeding in the commercialization of the world's first human iPS cell products in 2009 and with the world's most advanced research and technology. In addition, through the recent acquisitions of Reinnervate (UK), BioServe (US), and Stemgent (US), ReproCELL is proceeding towards the establishment of a global distribution network, and technology synergy and new product introductions.
|
|
|
|
|
|
|
|
|
|
Stemgent
|
|
Pharmaceuticals & Biotechnology
|
private:stemgent
|
345803
|
Feb 12th, 2018 12:00AM
|
Stemgent, Inc.
|
1.2K
|
19.00
|
Open
|
Biotechnology
|
Feb 12th, 2017 04:15AM
|
Feb 12th, 2017 04:15AM
|
Stemgent, part of the ReproCELL Group, is a leading supplier of cellular reprogramming products and services and tissue-based research, and provides a comprehensive portfolio of tools for cell research, and is recognized as expert in stem cell reprogramming, provide mRNA reprogramming systems, cell culture media, antibodies, small molecules, and iPS reprogramming services.
ReproCELL Incorporated
ReproCELL was established as a venture company originating from the University of Tokyo and Kyoto University and has been the pioneer in the iPS cell business, succeeding in the commercialization of the world's first human iPS cell products in 2009 and with the world's most advanced research and technology. In addition, through the recent acquisitions of Reinnervate (UK), BioServe (US), and Stemgent (US), ReproCELL is proceeding towards the establishment of a global distribution network, and technology synergy and new product introductions.
|
|
|
|
|
|
|
|
|
|
Stemgent
|
|
Pharmaceuticals & Biotechnology
|
private:stemgent
|
345803
|
Feb 11th, 2018 12:00AM
|
Stemgent, Inc.
|
1.2K
|
19.00
|
Open
|
Biotechnology
|
Feb 11th, 2017 05:35AM
|
Feb 11th, 2017 05:35AM
|
Stemgent, part of the ReproCELL Group, is a leading supplier of cellular reprogramming products and services and tissue-based research, and provides a comprehensive portfolio of tools for cell research, and is recognized as expert in stem cell reprogramming, provide mRNA reprogramming systems, cell culture media, antibodies, small molecules, and iPS reprogramming services.
ReproCELL Incorporated
ReproCELL was established as a venture company originating from the University of Tokyo and Kyoto University and has been the pioneer in the iPS cell business, succeeding in the commercialization of the world's first human iPS cell products in 2009 and with the world's most advanced research and technology. In addition, through the recent acquisitions of Reinnervate (UK), BioServe (US), and Stemgent (US), ReproCELL is proceeding towards the establishment of a global distribution network, and technology synergy and new product introductions.
|
|
|
|
|
|
|
|
|
|
Stemgent
|
|
Pharmaceuticals & Biotechnology
|
private:stemgent
|
345803
|
Feb 10th, 2018 12:00AM
|
Stemgent, Inc.
|
1.2K
|
19.00
|
Open
|
Biotechnology
|
Feb 10th, 2017 06:43AM
|
Feb 10th, 2017 06:43AM
|
Stemgent, part of the ReproCELL Group, is a leading supplier of cellular reprogramming products and services and tissue-based research, and provides a comprehensive portfolio of tools for cell research, and is recognized as expert in stem cell reprogramming, provide mRNA reprogramming systems, cell culture media, antibodies, small molecules, and iPS reprogramming services.
ReproCELL Incorporated
ReproCELL was established as a venture company originating from the University of Tokyo and Kyoto University and has been the pioneer in the iPS cell business, succeeding in the commercialization of the world's first human iPS cell products in 2009 and with the world's most advanced research and technology. In addition, through the recent acquisitions of Reinnervate (UK), BioServe (US), and Stemgent (US), ReproCELL is proceeding towards the establishment of a global distribution network, and technology synergy and new product introductions.
|
|
|
|
|
|
|
|
|
|
Stemgent
|
|
Pharmaceuticals & Biotechnology
|
private:stemgent
|
345803
|
Feb 9th, 2018 12:00AM
|
Stemgent, Inc.
|
1.2K
|
19.00
|
Open
|
Biotechnology
|
Feb 9th, 2017 08:57AM
|
Feb 9th, 2017 08:57AM
|
Stemgent, part of the ReproCELL Group, is a leading supplier of cellular reprogramming products and services and tissue-based research, and provides a comprehensive portfolio of tools for cell research, and is recognized as expert in stem cell reprogramming, provide mRNA reprogramming systems, cell culture media, antibodies, small molecules, and iPS reprogramming services.
ReproCELL Incorporated
ReproCELL was established as a venture company originating from the University of Tokyo and Kyoto University and has been the pioneer in the iPS cell business, succeeding in the commercialization of the world's first human iPS cell products in 2009 and with the world's most advanced research and technology. In addition, through the recent acquisitions of Reinnervate (UK), BioServe (US), and Stemgent (US), ReproCELL is proceeding towards the establishment of a global distribution network, and technology synergy and new product introductions.
|
|
|
|
|
|
|
|
|
|
Stemgent
|
|
Pharmaceuticals & Biotechnology
|